- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00055536
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease
A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently taking Remicade. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-351.
Study Overview
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32605
- Digestive Disease Associates
-
Jacksonville, Florida, United States, 32223
- Borland Groover Clinic
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Atlanta Gastroenterology Associates
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Montana
-
Butte, Montana, United States, 59701
- Mercury Street Medical
-
-
New York
-
Great Neck, New York, United States, 11021
- Long Island Clinical Research Associates, LLP
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Asheville Gastroenterology
-
Raleigh, North Carolina, United States, 27612
- Wake Research Associates
-
Rocky Mount, North Carolina, United States, 27804
- Boice-Willis Clinic
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Columbia Gastroenterology Associates
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Memphis Gastroenterology Group
-
Memphis, Tennessee, United States, 38120
- Gastroenterology Center Of The Midsouth
-
-
Texas
-
Austin, Texas, United States, 78745
- Austin Gastroenterology
-
-
Virginia
-
Danville, Virginia, United States, 24541
- Internal Medicine Associates
-
Virginia Beach, Virginia, United States, 23455
- Gastroenterology Consultants
-
-
Washington
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
Tacoma, Washington, United States, 98405
- Digestive Health Specialists
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Male and female patients at least 18 years of age with at least a six-month history of Crohn's disease and who are currently receiving Remicade and are not in remission (CDAI greater than/equal to 150)
- Women must not be breastfeeding or pregnant, and must not become pregnant during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CD306
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on natalizumab
-
BiogenElan Pharmaceuticals; United BioSource, LLCCompleted
-
BiogenElan PharmaceuticalsWithdrawn
-
BiogenElan PharmaceuticalsCompletedCrohn's DiseaseUnited States
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisFrance, Italy, Spain, Germany, Belgium
-
BiogenElan PharmaceuticalsCompleted
-
BiogenElan PharmaceuticalsCompletedCrohn's DiseaseUnited States
-
BiogenElan PharmaceuticalsCompletedCrohn's DiseaseUnited States, United Kingdom
-
University at BuffaloCompleted
-
University Hospital, CaenBiogenCompletedMultiple Sclerosis, Relapsing-RemittingFrance
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisIreland